bpac 2010 laboratory of hemostasis l.
Skip this Video
Loading SlideShow in 5 Seconds..
BPAC 2010 Laboratory of Hemostasis PowerPoint Presentation
Download Presentation
BPAC 2010 Laboratory of Hemostasis

Loading in 2 Seconds...

play fullscreen
1 / 45

BPAC 2010 Laboratory of Hemostasis - PowerPoint PPT Presentation

  • Uploaded on

BPAC 2010 Laboratory of Hemostasis. Basil Golding M.D. Director, Division of Hematology OBRR/CBER/FDA. Laboratory of Hemostasis. Research/Regulator Chava Kimchi-Sarfaty, Ph.D., Senior Staff Fellow Nobuko Katagiri, Ph.D., Staff Fellow Mikhail Ovanesov, Ph.D., Visiting Scientist

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

PowerPoint Slideshow about 'BPAC 2010 Laboratory of Hemostasis' - kimo

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
bpac 2010 laboratory of hemostasis

BPAC 2010 Laboratory of Hemostasis

Basil Golding M.D.

Director, Division of Hematology


laboratory of hemostasis
Laboratory of Hemostasis


  • Chava Kimchi-Sarfaty, Ph.D., Senior Staff Fellow
    • Nobuko Katagiri, Ph.D., Staff Fellow
  • Mikhail Ovanesov, Ph.D., Visiting Scientist
  • Andrey Sarafanov, Ph.D., Chemist
  • Zuben Sauna, Ph.D., Visiting Scientist
laboratory of hemostasis5
Laboratory of Hemostasis

Full-time Regulatory Reviewers

  • Natalya Ananyeva, Ph.D., Visiting Scientist
  • Roman Drews, Ph.D., Chemist
  • Don Lebel, B.S., Medical Technologist

( Retired in June 2010)

  • Tim Lee, Ph.D., Chemist/Acting Chief
  • Ze Peng, Ph.D., Visiting Associate
  • Laura Wood, M.S. Biologist
licensed products regulated by lh
Licensed products regulated by LH
  • Coagulation Factors
    • Factors VIII and IX (Human plasma-derived & Recombinant)
    • Factor VIII/von Willebrand Factor Complex (Human plasma-derived)
    • Fibrinogen Concentrate
  • “Bypassing” Products
    • AICC (e.g., FEIBA)
    • Recombinant activated Factor VII
  • Hemostatic Agents
    • Thrombin (Bovine, Human & Recombinant)
    • Fibrin Sealant
    • CryoSeal FS System
    • Fibrin Sealant Patch
  • Anti-coagulants
    • Protein C
    • Antithrombin III (Human plasma-derived & Transgenic)
laboratory of hemostasis regulatory responsibilities
Laboratory of HemostasisRegulatory Responsibilities
  • Review applications for:
    • Investigational products
    • Marketing of new products
    • Changes in manufacturing of, or indications for licensed products
  • Lot release testing of licensed products
  • Inspection of manufacturing facilities
    • Compliance and enforcement actions
laboratory of hemostasis regulatory responsibilities cont
Laboratory of HemostasisRegulatory Responsibilities (Cont.)
  • Review of Biological Product Deviation Reports
    • Assessment of risk and response
  • Develop policy and guidance
    • Product safety and efficacy
    • Patient and physician information
    • Current Good Manufacturing Practices
  • Pre-submittal Support
    • Review of briefing material
    • Meeting with sponsors
    • Preparation of summaries
regulatory activities 2005 2010
Regulatory Activities 2005 - 2010

BLA Approvals

  • CEPROTIN (p.d. human Protein C)
  • RECOTHROM (rec. human thrombin)
  • EVITHROM (p.d. human thrombin)
  • XYNTHA (rec. human Factor VIII)
  • ARTISS (p.d. human fibrin sealant)
  • RiaSTAP (p.d. human fibrinogen)
  • ATRYN (transgenic human ATIII)
  • WILATE (p.d. human vWF/FVIII complex)
  • TachoSil (Fibrin Sealant Patch)
    • Fibrinogen BDS (p.d. human)
    • Thrombin BDS (p.d. human)
regulatory activities 2005 2010 cont d
Regulatory Activities 2005 – 2010 cont’d

Reviewed over

  • 400 BLA Supplements
  • 100 Annual Reports
  • 100 other miscellaneous submissions
  • 1600 lots tested for release
  • 50 original IND’s & their associated amendments

Participated in

  • Facility inspections on-site and by phone
  • International calibration studies for reference standards
emerging products
Emerging Products
  • Recombinant porcine Factor VIII
  • PEGylated coagulation factors
  • Fc coagulation factor fusions
    • Improve potency, expression, clearance
  • Proteins for rare bleeding disorders:
    • Factor XIII
    • Factor XI
    • Factor X
    • rADAMTS13
    • von Willebrand Factor (recombinant)
Toward More Effective Treatment of Blood Clotting Disorders: Pharmacogenomic Studies of ADAMTS13 and Related Proteins

Chava Kimchi-Sarfaty, Ph.D.

Laboratory of Hemostasis



FDA Mission Relevance:Pharmacogenomics of Products Regulated by FDA

New concept paper/guidance on clinical pharmacogenomics discusses the following issues:

  • FDA’s current view on whether or not clinical pharmacogenomic studies should be performed
  • General strategies for using pharmacogenomic information in drug development
  • Design of clinical pharmacogenomic studies
  • Incorporation of pharmacogenomics information on the drug label

However, currently there are no regulations or guidelines vis à vis the choice of sequence in the development of a recombinant therapeutic protein


What is a SNP?

  • SNP: Single-nucleotide polymorphism
  • Synonymous SNP: No change in amino-acid sequence
  • Non-synonymous SNP: Altered amino-acid sequence
  • Polymorphism: DNA variation in which sequence is present in at least 1% of the population
  • Most common type of genetic variation
    • May occur every 100-300 bases

Potential effect of SNPs on protein structure and function


on protein



For Protein


Protein Expression

Protein sequence

Protein conformation

Truncated protein






  • Understand the consequence of synonymous and non-synonymous mutations and SNPs on the development of recombinant therapeutic proteins
  • Develop tools to predict the consequences of changes made to wild-type sequence during manufacture of recombinant therapeutic proteins



Frame shift


SNPs in the ADAMTS13 protein that were investigated in our laboratory


CUB1 and 2




SNP studied by our lab

  • Bolded SNPs indicate syn. SNPs
  • Red letter indicates the nucleotide that was changed within the variant codon

In Silico Studies

I. ADAMTS13, the von Willebrand Factor (VWF) cleaving protease:

We have completed the in silico studies of twelve Single Nucleotide Polymorphisms (SNPs) in ADAMTS13, located in various domains of the protein:

The results of these in silico studies were compared to in vitro studies


In vitro studies of twelve ADAMTS13 SNPs





Real Time-






mRNA levels

Intracellular protein levels & conformation changes

ADAMTS13 activity

Protein conformational changes

Intracellular and extracellular protein levels

  • High correlation between in silico & in vitro studies provides tools to examine the effect of mutations on therapeutic proteins
  • We demonstrate that both synonymous and non-synonymous mutations affect protein expression, conformation and/or function

II. Factor IX:

In silico and in vitro studies of synonymous mutation Val107Val in F9 gene, found in five unrelated Swedish Hemophilia B patients:

In silico and in vitro assays performed as described previously for ADAMTS13


  • Computational analyses suggest that the synonymous V107V mutation in F9, located at a region critical for protein folding, could change translation rate/rhythm, therefore affecting the protein’s conformation.
  • Experimental analyses demonstrated a significant change in conformation between Val107Val mutation and WT.
future studies
Future Studies
  • Develop new assays that can differentiate between different molecular forms of ADAMTS13, VWF, FVIII, and FIX based on increased sensitivity
  • Characterize ADAMTS13 SNPs in healthy, non-TTP individuals and correlate the in vitro analyses with in vivo characterization
  • Characterize additional FIX SNPs and mutations using in silico and in vitro analyses
  • Study WT vs. V107V FIX in hemophilia B knock-down mice

Importance of project to the FDA

  • The FDA has been regulating biotechnology-derived protein products since the 1980s
  • More than 200 biopharmaceutical proteins have now been approved
  • Widespread use of biopharmaceuticals has demonstrated that nearly all biologicals can elicit antibody responses
  • Inhibitory antibodies to therapeutic proteins compromise efficacy and also cross-react with endogenous factors to cause serious toxicity
  • Even non-inhibitory antibodies can complicate interpretation of the toxicity, pharmacokinetic and pharmacodynamic data

Specific aims

  • Develop computational and in vitro methods for the pre-clinical identification of T-cell epitopes on the FVIII protein
  • Determine the role of sequence mismatch between the endogenous (albeit non-functional) and infused FVIII in eliciting immunogenicity
  • Pharmacogenetics and the development of inhibitory antibodies to FVIII:

Evaluate genetic variability in the endogenous F8 gene vis- à-vis polymorphisms as a risk-factor for immunogenicity

Evaluate HLA restriction of patients (in the context of sequence mismatch) as a risk-factor for immunogenicity


Accomplishments (1)

  • Computational predictions of peptide binding to specific MHC proteins, using 56 FVIII peptides, correlate well with in vitro binding measurements using purified recombinant MHC Class II alleles (p value = 0.000065).
  • Historical data shows that some missense mutations in the FVIII gene are associated with inhibitory antibodies while others are not. A missense mutation results in a localized mismatch between the sequence of the endogenous and infused FVIII (i.e. peptides from this region are foreign). An ‘immunogenicity score’ devised by us discriminates between mutations that do and do not elicit inhibitory antibodies (p value = 0.008).
  • A recent report suggests that African Americans develop inhibitory antibodies at higher frequencies due to the greater diversity in F8 gene polymorphisms in these patients. Peptides that span SNPs associated with inhibitory antibodies bind with higher affinity to MHC alleles commonly found in African Americans.

Accomplishments (2)

  • Demonstration that cells and tissue samples from hemophilia A (HA) patients with the intron 22 inversion (I22I) synthesize the entire FVIII polypeptide chain; however the primary sequence is contained in two polypeptide chains
  • The I22I represents ~50% of severe HA patients; the immunological implication of our finding is that these patients (despite a large gene alteration) may be tolerized to the FVIII protein


A pharmacogenetic approach, based on individual patients, is necessary for the accurate prediction of immunogenicity

The extent and position of sequence mismatch between the endogenous and infused FVIII (due to disease causing mutations and SNPs) and the HLA restriction of the patient are important risk-factors for immunogenicity


Future Plans

  • Develop a hierarchical decision making tool for individualized immunogenicity risk assessment for HA patients using clinical samples to test our hypotheses
  • Develop strategies to reduce the disproportionate frequency of adverse alloimmune events in vulnerable populations
  • Determine whether principles developed in FVIII for a personalized assessment of immunogenicity risk can be applied to therapeutic proteins in general
mikhail v ovanesov phd

Mikhail V Ovanesov, PhD

Study of the regulation of blood coagulation kinetics

Public Health Issue:
  • Existing clinical assays of blood coagulation have poor

predictive value

  • Coagulation testing can be improved to reflect physiological conditions

Research Approach

  • Development and optimization of novel assays that measure ‘global’ hemostasis function
  • Investigation of potency and thrombogenicity of FVIIa, FIXa and FXIa

Regulatory Contribution:

  • Product evaluation
  • Enhancing the assurance of the efficacy, safety and quality of coagulation products
program is technique based a 7 year plan
Program is technique-based: a 7-year plan

Assay development

Assay application

2009 2010 2011 2012 2013 2014 years

Thrombin generation test

Mechanism of Action,

Potency, Thrombogenicity


Clot growth assay



Coagulation in mouse

(deep tissue imaging)


Development of the Thrombin Generation Test to facilitate the characterization and regulation of plasma-derived products
  • Funded by the FDA CBER Modernization Science

Research goals:

  • Optimization of the assay for hemophilia treatments and thrombogenicity
  • Comparative analysis of commercially available and in house TGT variants
  • Application to outstanding regulatory issues
    • e.g.compare products with known controversies in potency assessment (Factor VIII and Factor VIIa variants)
applying thrombin generation test to study thrombogenicity of igiv samples case study
Applying Thrombin Generation Test to study thrombogenicity of IGIV samples(Case study)
  • Octagam® (Octapharma): immunoglobulin intravenous (IGIV)
  • 2010: High incidence of Thrombotic Adverse Events (TAE): strokes, myocardial infarctions
  • Our testing indicated a possible root cause for TAEs: Factor XIa is the likely contaminant
  • As a result of TAEs and TGT-based testing, Octapharma voluntarily withdrew the product from the U.S. market (September 2010)
research in progress application of videomicroscopy to igiv thrombogenicity testing
Research in progress: application of videomicroscopy to IGIV thrombogenicity testing

Thrombosis-implicated lots

Control non-implicated lots

Negative control (buffer)

  • 40 minutes of video shooting
  • Factor XI-deficient plasma
  • supplemented with IGIV product
  • (4 different lots) or buffer
ongoing efforts of our research team
Ongoing efforts of our research team
  • Distribution of the CBER TGT protocol among all major IGIV manufacturers
  • Screening of marketed plasma derived products for thrombogenic contaminants
  • Collaboration with other regulatory agencies and industry
  • Development of thrombogenicity standards (with NIBSC, PEI, EMA)
andrey sarafanov ph d

Andrey Sarafanov Ph.D.

Identification of Binding Sites on Coagulation Factor VIII (FVIII) for its Catabolic Receptors:

Low-Density Lipoprotein Receptor (LDLR)

Low-Density Lipoprotein Receptor-Related Protein (LRP)


Relevance of the project to FDA mission:

  • Deficiency in Factor VIII (FVIII) results in coagulation disorder (Hemophilia A). The disease is treated by infusions of FVIII products
  • Currently, new FVIII products with prolonged time in the circulation are under development by pharmaceutical companies
  • Regulation of these products requires an understanding ofthe mechanisms of FVIII clearance from the circulation

The Highlights of the Project

LRP and LDLR: Expressed in the liver, and catabolize various ligands (plasma lipoproteins etc). Cooperate in clearance of FVIII: deficiency in both receptors results in prolongation of the half-life of FVIII by 5 times in mice

The ongoing project involves: establishing expression of FVIII, LRP and LDL fragments, performing scanning mutagenesis of FVIII, testing interaction of the FVIII mutants with LRP and LDL in various in vitro and in vivo assays to determine the binding epitope(s) on FVIII.

Future Plans: Testing possibility of generation of "improved" (long-lasting) FVIII for better treatment of Hemophilia A. The “improved” FVIII would have a decrease in the affinities for LDLR and LRP, while retaining activity, but not more immunogenic



  • Evolutionarily related and similar in structure
  • Expressed in the liver, and serve a function to catabolize various ligands (plasma lipoproteins etc.)
  • Cooperate in clearance of FVIII: deficiency in both receptors results in prolongation of the half-life of FVIII by 5 times in mice
  • Molecular interactions of FVIII with LRP and LDLR are similar

Mapping the LRP- and LDLR-binding Site(s) on FVIII:

Selection of FVIII amino acid residues for scanning mutagenesis

Expression of fragments of FVIII, LDLR, LRP and FVIII mutants

Performing binding assays for FVIII variants and receptors’ fragments

Testing receptor-mediated internalization of FVIII variants in cell culture

Testing clearance of FVIII variants

in mice (normal, FVIII- and vWF-deficient)

Determination of critical residues of FVIII for binding to LRP






I. Ongoing Experiments: Expression of FVIII and its variants

Heavy Chain

Light Chain



















LRP (LDLR) -binding region

Constructs to be Generated

FVIII variants






Introduction of point mutations

Heavy Chain




Light Chain variants . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .





(~160 kDa)

Ligand-binding part

Hepatic cell


β-propeller domain

EGF-like repeats

Complement-type repeats

Transmembrane domain

Cytoplasmic domain

O-linked sugar domain

II. Ongoing Experiments: Expression of LDLR Fragments

Generated constructs:

(a minimal ligand-binding motif is composed by two adjacent CRs)

1) CR 1-7 . . . .

2) CR 1-2 . . . .

3) CR 2-3. . . . . . .

4) CR 3-4 . . . . . . . . .

5) CR 4-5 . . . . . . . . . . .

6) CR 5-6 . . . . . . . . . . . . . .

7) CR 6-7 . . . . . . . . . . . . . . . .


Future Plans

Generation of FVIII having a decrease in affinities for LDLR and LRP yet retaining the functional activity, and not increased immunogenicity.

The “improved” FVIII would have a longer half-life in the circulation, thus requiring less frequent infusions into Hemophilia A patients, and a reduced cost.